Key result
Atorvastatin treatment in monocrotaline-challenged rats reduced right ventricular pressure, hypertrophy, vascular remodeling, and 5-HTT expression over 4 weeks.
Why the study?
Does atorvastatin reduce pulmonary hypertension and alter 5-HTT expression in monocrotaline-challenged rats?
Does atorvastatin reduce pulmonary hypertension and alter 5-HTT expression in monocrotaline-challenged rats?
Atorvastatin effectively reduces monocrotaline-induced pulmonary hypertension in rats, an effect associated with decreased expression of the serotonin transporter protein (5-HTT).
Answers are grounded in this paper and cite their sources.
Should not change clinical practice in pulmonary hypertension; hypothesis-generating for atorvastatin effects on 5-HTT in animal models.
HMG-CoA-reductase inhibitors (statins) influence lipid metabolism and have pleiotropic effects. Several statins reduce various forms of pulmonary hypertension (PH) in animal models. The relationship between atorvastatin and expression of serotonin transporter protein (5-HTT) remains unknown. This study focused on the effects of atorvastatin on the course of monocrotaline (MCT)-induced PH and its relation to 5-HTT expression. Male Sprague-Dawley rats were challenged with MCT with or without subsequent daily oral treatment with 0.1, 1, and 10 mg/kg of atorvastatin for 28 days. Over the 4-wk course, the progression of PH was followed by transthoracic echocardiography [pulmonary artery pressure was assessed by pulmonary artery flow acceleration time (PAAT), an estimate reciprocal to pulmonary artery pressure], and, at the end of the 4-wk course, invasive right ventricular pressure, right ventricular weight, quantitative morphology, and 5-HTT expression were measured. MCT caused significant PH as early as 7 days after injection. Atorvastatin treatment increased PAAT and reduced right ventricular pressure, right ventricular hypertrophy, and vascular remodeling over the 4-wk course. MCT challenge was associated with increased pulmonary vascular 5-HTT expression, and atorvastatin treatment reduced the 5-HTT expression. MCT-induced PH over the course of 4 wk can be easily followed by transthoracic echocardiography, and atorvastatin is effective in reducing the PH. Atorvastatin's effects are associated with a decrease of 5-HTT expression.
No takes yet. Share an insight, caveat, or question.
Laudi et al. (2007) studied Pulmonary hypertension. Atorvastatin vs. Monocrotaline without atorvastatin was evaluated on Progression of pulmonary hypertension (PAAT, right ventricular pressure, right ventricular weight, vascular remodeling, and 5-HTT expression). Atorvastatin treatment in monocrotaline-challenged rats reduced right ventricular pressure, hypertrophy, vascular remodeling, and 5-HTT expression over 4 weeks.
Synapse has enriched 10 related papers. Consider them for comparative context: